CorpDigest
Bayer AG
Leadership History
5 leaders · Full leadership timeline
Last reviewed: 2025-07-15 · By Swet Parvadiya
Thousands of additional cases followed. The US Supreme Court declined to hear Bayer's appeal in 2022. Kerendia for chronic kidney disease in Type 2 diabetes patients addresses a large population with limited treatment options. The Monsanto acquisition is carried at its purchase price minus accumulated amortization and impairments. Barmen, Germany, 1863. Bayer et comp. IG Farben was broken up by the Allied Control Council after World War II. The 2006 acquisition of Schering AG for €17 billion added a women's health and oncology portfolio that transformed the pharmaceutical segment from a mid-sized operation into a major global franchise. The Monsanto deal is now one of the most studied examples of catastrophic acquisition due diligence failure in business history. The company rebuilt after the war within the IG Farben chemical conglomerate, the trust that consolidated the German chemical industry in the 1920s.
Chairman and Managing Director
Friedrich Bayer Jr., son of the founder, joined the company as a chemist in 1873 and became the driving force behind its scientific expansion. He led the diversification from dyestuffs into pharmaceuticals, culminating in the 1899 launch of Aspirin, and oversaw the company's growth into a global chemical enterprise before his death in 1920.
Chairman and Managing Director
Carl Duisberg joined Bayer in 1888 and became the dominant figure in its expansion. He led the development of Aspirin into a global brand, established Bayer's first foreign subsidiaries, and was the architect of the 1925 merger into IG Farben. His leadership transformed Bayer from a regional dyestuffs maker into an international chemical conglomerate.
Chairman of the Board of Management
Wenning led Bayer's strategic transformation from a diversified chemical conglomerate to a focused life sciences company. He oversaw the 2006 Schering acquisition and initiated the process that led to the 2015 Covestro spin-off, establishing the three-division structure that defines Bayer today.
Chairman of the Board of Management and CEO
Baumann championed and executed the $66 billion Monsanto acquisition, the largest in German corporate history. He defended the deal against shareholder criticism and managed the initial litigation response, including the $10.9 billion settlement. He stepped down in 2023 after the company's market value declined by over 60% during his tenure.
Chairman of the Board of Management and CEO
Anderson, the first American CEO in Bayer's 162-year history, launched the Dynamic Shared Ownership transformation, cutting over 12,000 positions and halving management ranks. He has prioritized pharmaceuticals pipeline development (Nubeqa, Kerendia), Crop Science profitability, balance sheet deleveraging, and litigation containment. His contract was extended through March 2029 by unanimous Supervisory Board decision.
The litigation overhang remains the single most consequential risk. The business model is consumer-packaged-goods-like: lower margins than pharmaceuticals but more stable, recurring revenues with less patent cliff risk. Consumer Health faces competitive pressure from private-label alternatives, retailer consolidation (especially in the U.S. Where Walmart and Amazon dominate), and category-specific challenges such as a soft cold and flu season that reduced allergy and cold product sales. The North American exposure is particularly significant because it concentrates both the highest-margin pharmaceutical sales and the highest-risk litigation exposure.
The competitive challenge is that Novo Nordisk's Ozempic and Eli Lilly's Mounjaro are reshaping diabetes treatment paradigms, potentially reducing the diabetic kidney disease population that Kerendia targets. The most immediate threat to Bayer's margin and market position is the accelerating generic erosion of Xarelto (rivaroxaban), the oral anticoagulant that was once the company's largest pharmaceutical revenue generator. The Crop Science division faces a parallel structural challenge. The Xarelto patent litigation adds further pharmaceutical-specific legal risk, with increased costs recorded in 2024 'mainly related to Xarelto patents.' The Dicamba drift lawsuits — alleging that Monsanto's dicamba herbicide damaged neighboring crops — have generated additional claims.
Werner Baumann, Bayer's CEO from 2016-2022, staked his tenure on the Monsanto acquisition — presented to shareholders at Bayer's 2018 AGM without advance notice, passing by only a 55% vote — and ultimately resigned in April 2022 unable to resolve the Roundup litigation that the acquisition had inherited. Baumann had argued that combining agri-chemistry with seeds would create unbeatable competitive advantages in sustainable agriculture, and initially defended the strategic rationale as glyphosate lawsuits mounted. As settlements reached €10.9 billion with no end in sight, Baumann's position became untenable, and his resignation was framed as a 'personal decision' but reflected board loss of confidence in his ability to resolve the litigation crisis that defined and ultimately ended his tenure.
Bill Anderson joined as Bayer CEO in June 2023 after leading Roche's pharmaceutical division, bringing an American biotech management philosophy that contrasted sharply with Bayer's German industrial corporate culture. Anderson immediately launched 'Dynamic Shared Ownership' eliminating conventional management hierarchy, planned 10,000+ job cuts targeting €2+ billion in annual savings, and proposed splitting Bayer into separate pharmaceutical and crop science companies to unlock conglomerate discount. Anderson's stated belief that Bayer's pharmaceutical pipeline deserves to be valued as a pure-play biotech company, unencumbered by agricultural litigation liability, drives his restructuring thesis — a radical departure from predecessors who defended the integrated conglomerate model.
Marijn Dekkers, Bayer CEO from 2010-2016, executed two major acquisitions that reshaped Bayer's portfolio: the €12.3 billion purchase of Merck's consumer care business (bringing Claritin, Coppertone, and Dr. Scholl's) in 2014 and the spin-off of the materials science division as Covestro in 2015. Dekkers' strategy built Bayer into a focused life sciences company — pharmaceuticals and consumer health — by shedding industrial chemicals, and the Merck consumer care deal created today's Bayer Consumer Health division generating €6 billion annually. He stepped down in April 2016 having transformed Bayer from a diversified industrial company into a more focused life sciences business, but the subsequent Monsanto acquisition by his successor undid much of the strategic clarity he had established.
Bayer CEOs have repeatedly faced the question of whether a conglomerate spanning pharmaceuticals, consumer health, and agricultural chemicals creates or destroys value versus focused pure-plays, with each leader reaching different conclusions. Dekkers spun off materials science to focus on life sciences; Baumann doubled down on the conglomerate model by adding agricultural chemicals; Anderson now proposes splitting the conglomerate into separate companies. This oscillation reflects genuine strategic uncertainty: Bayer's divisions are highly dissimilar businesses requiring different management capabilities, capital allocation, and investor audiences, but separating them would sacrifice tax benefits, shared infrastructure, and the cash flow diversification that has allowed Bayer to absorb the Monsanto litigation without bankruptcy.